- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Role of Genetic vs Genomic Testing in Cancer
“When I think about genetic testing, I think about screening,” says David C. Collymore, MD, MBA. In his opinion, genetic testing finds application in “screening large populations of people to see who is susceptible to certain illnesses.”
Genomic testing, on the other hand, has application following diagnosis, according to Dr Collymore. “When an illness has been identified, what treatment can be tailored to improve the outcomes of that individual? One is a screening mindset and the other a treatment mindset,” Dr Collymore explained.
It is necessary, though, to consider the cost-to-benefit ratio for these tests, he advised. “With any screening modality, you want to ensure that the cost of the screening mechanism, over a broader population, makes it an effective [to detect] illnesses in that broader population,” said Dr Collymore.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
